Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024407 · ClinicalTrials.gov registry record · Phase 1
A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.
A Phase 1 study of Heterotopic Ossification (HO), sponsored by Ashibio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07024407: Recruiting Phase 1 study of Heterotopic Ossification (HO), sponsored by Ashibio.
NCT07024407 is a Phase 1 study of Heterotopic Ossification (HO) that is actively recruiting participants, run by Ashibio. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07024407, a Phase 1 study of Heterotopic Ossification (HO), is actively recruiting participants, sponsored by Ashibio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label study of andecaliximab in participants at risk of developing bone where bone should not be, such as in muscle, tendons, and other soft tissues following traumatic spinal cord injury. The goal of this study is to assess the safety of andecaliximab, how much drug is in the body over time (pharmacokinetics/PK), and how it affects the body (pharmacodynamics/PD) in participants who have had a recent traumatic spinal cord injury.
Primary Outcome
Incidence and severity of all serious adverse events (SAEs) and all treatment-emergent adverse events (TEAEs)
Conditions Studied
Interventions
- DRUG Andecaliximab
Study Locations (1)
Colorado
- Craig Hospital - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-05-14 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
What NCT07024407 shows while recruiting
NCT07024407 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Heterotopic Ossification (HO) appearing as the primary indexed condition, and to 1 intervention - of which Andecaliximab is the first listed.
NCT07024407 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT07024407 about?
NCT07024407 is a clinical study titled "A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.". This is an open-label study of andecaliximab in participants at risk of developing bone where bone should not be, such as in muscle, tendons, and other soft tissues following traumatic spinal cord injury. The goal of this study is to assess the safety of andecaliximab, how much drug is in the body o...
What is the current status of trial NCT07024407?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-05-14. Estimated completion is 2026-01.
What conditions does trial NCT07024407 study?
This clinical trial studies the following conditions: Heterotopic Ossification (HO).
What interventions are being tested in trial NCT07024407?
The interventions under investigation include: Andecaliximab (DRUG).
Who is sponsoring clinical trial NCT07024407?
This trial is sponsored by Ashibio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024407 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07024407's enrollment target sits among peer trials
10 1914th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI